PortfoliosLab logoPortfoliosLab logo
VOR vs. ENTA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VOR vs. ENTA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Vor Biopharma Inc. (VOR) and Enanta Pharmaceuticals, Inc. (ENTA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, VOR achieves a 9.79% return, which is significantly higher than ENTA's -24.54% return.


VOR

1D
1.92%
1M
-9.74%
YTD
9.79%
6M
14.79%
1Y
246.86%
3Y*
-48.18%
5Y*
-49.22%
10Y*

ENTA

1D
3.39%
1M
-15.18%
YTD
-24.54%
6M
-19.21%
1Y
60.59%
3Y*
-21.72%
5Y*
-24.07%
10Y*
-6.52%
*Multi-year figures are annualized to reflect compound growth (CAGR)

VOR vs. ENTA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
VOR
Vor Biopharma Inc.
9.79%-41.08%-50.67%-66.17%-42.77%-72.35%
ENTA
Enanta Pharmaceuticals, Inc.
-24.54%174.26%-38.89%-79.77%-37.79%42.17%

Correlation

The correlation between VOR and ENTA is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.27

Correlation (3Y)
Calculated over the trailing 3-year period

0.26

Correlation (5Y)
Calculated over the trailing 5-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Feb 5, 2021

0.29

Fundamentals

Market Cap

VOR:

$617.65M

ENTA:

$343.81M

EPS

VOR:

-$53.66

ENTA:

-$2.67

Total Revenue (TTM)

VOR:

$0.00

ENTA:

$69.21M

Gross Profit (TTM)

VOR:

-$23.00K

ENTA:

$33.44M

EBITDA (TTM)

VOR:

-$1.13B

ENTA:

-$61.85M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VOR vs. ENTA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VOR
VOR Risk / Return Rank: 8383
Overall Rank
VOR Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
VOR Sortino Ratio Rank: 9090
Sortino Ratio Rank
VOR Omega Ratio Rank: 8888
Omega Ratio Rank
VOR Calmar Ratio Rank: 8383
Calmar Ratio Rank
VOR Martin Ratio Rank: 7373
Martin Ratio Rank

ENTA
ENTA Risk / Return Rank: 7272
Overall Rank
ENTA Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
ENTA Sortino Ratio Rank: 7878
Sortino Ratio Rank
ENTA Omega Ratio Rank: 7777
Omega Ratio Rank
ENTA Calmar Ratio Rank: 7373
Calmar Ratio Rank
ENTA Martin Ratio Rank: 7070
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VOR vs. ENTA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Vor Biopharma Inc. (VOR) and Enanta Pharmaceuticals, Inc. (ENTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


VORENTADifference
Sharpe ratioReturn per unit of total volatility

+0.89

Sortino ratioReturn per unit of downside risk

+1.02

Omega ratioGain probability vs. loss probability

1.38

1.27

+0.11

Calmar ratioReturn relative to maximum drawdown

2.85

1.78

+1.08

Martin ratioReturn relative to average drawdown

4.09

3.36

+0.73

VOR vs. ENTA - Sharpe Ratio Comparison

The current VOR Sharpe Ratio is 1.45, which is higher than the ENTA Sharpe Ratio of 0.56. The chart below compares the historical Sharpe Ratios of VOR and ENTA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

VOR vs. ENTA - Drawdown Comparison

The maximum VOR drawdown since its inception was -99.72%, roughly equal to the maximum ENTA drawdown of -96.63%. Use the drawdown chart below to compare losses from any high point for VOR and ENTA.


Loading charts...

Drawdown Indicators


VORENTADifference

Max Drawdown

Largest peak-to-trough decline

-99.72%

-96.63%

-3.09%

Max Drawdown (1Y)

Largest decline over 1 year

-87.15%

-34.30%

-52.85%

Max Drawdown (3Y)

Largest decline over 3 years

-97.03%

-82.38%

-14.65%

Max Drawdown (5Y)

Largest decline over 5 years

-99.32%

-95.62%

-3.70%

Max Drawdown (10Y)

Largest decline over 10 years

-96.63%

Current Drawdown

Current decline from peak

-98.67%

-90.58%

-8.09%

Average Drawdown

Average peak-to-trough decline

-88.69%

-49.27%

-39.42%

Ulcer Index

Depth and duration of drawdowns from previous peaks

60.71%

18.11%

+42.60%

Volatility

VOR vs. ENTA - Volatility Comparison

Vor Biopharma Inc. (VOR) has a higher volatility of 23.24% compared to Enanta Pharmaceuticals, Inc. (ENTA) at 13.67%. This indicates that VOR's price experiences larger fluctuations and is considered to be riskier than ENTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


VORENTADifference

Volatility (1M)

Calculated over the trailing 1-month period

23.24%

13.67%

+9.57%

Volatility (6M)

Calculated over the trailing 6-month period

68.60%

35.48%

+33.12%

Volatility (1Y)

Calculated over the trailing 1-year period

171.72%

109.73%

+61.99%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

116.35%

73.36%

+42.99%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

116.73%

60.69%

+56.04%

Dividends

VOR vs. ENTA - Dividend Comparison

Neither VOR nor ENTA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VOR vs. ENTA - Financials Comparison

This section allows you to compare key financial metrics between Vor Biopharma Inc. and Enanta Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M202220232024202520260
17.16M
(VOR) Total Revenue
(ENTA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


VOR and ENTA have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

VOR has higher volatility (23.24%) compared to ENTA (13.67%). In terms of maximum drawdown, VOR dropped -99.72% vs ENTA's -96.63%.

VOR currently has the higher Sharpe Ratio (1.45 vs 0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for VOR and ENTA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer